| P50 | author | Jenny Permuth-Wey | Q38299626 |
| P2093 | author name string | Tuya Pal | |
| | Alan Cantor | |
| | Rebecca Sutphen | |
| | Rachna Kapoor | |
| P2860 | cites work | BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure | Q27639649 |
| | Cancer statistics, 2001 | Q28189339 |
| | Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks | Q28609912 |
| | The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews | Q29619407 |
| | Managing the care of patients with advanced ovarian cancer. | Q33540038 |
| | Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary | Q33900686 |
| | Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. | Q34094654 |
| | Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer | Q34113283 |
| | The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group | Q34141842 |
| | Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing | Q34144140 |
| | BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients | Q34444787 |
| | Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium | Q34724404 |
| | BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study | Q36696220 |
| | Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden | Q38503154 |
| | Characteristics relating to ovarian cancer risk: implications for prevention and detection | Q40579680 |
| | Is early detection of ovarian cancer possible? | Q40934474 |
| | BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). | Q41056489 |
| | Mutation analysis of the BRCA1 gene in ovarian cancers. | Q41674947 |
| | Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer | Q41745402 |
| | Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium | Q42950856 |
| | Hereditary ovarian cancer in Poland. | Q43683502 |
| | Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology | Q43754824 |
| | BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases | Q44221699 |
| | Improved survival in women with BRCA-associated ovarian carcinoma | Q46693199 |
| | Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals | Q46796026 |
| | Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation | Q48070015 |
| | Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors | Q57250723 |
| | Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of aBRCA1orBRCA2Mutation | Q57250729 |
| | Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1 | Q63183299 |
| | Screening for early ovarian cancer | Q72530860 |
| | Familial ovarian cancer | Q72662961 |
| | Contribution of BRCA1 mutations to ovarian cancer | Q73215230 |
| | Clinicopathologic features of BRCA-linked and sporadic ovarian cancer | Q73782102 |
| | An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10 | Q73912443 |
| | Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations | Q73939659 |
| | Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1 | Q74361088 |
| | Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group | Q74462145 |
| | BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing | Q74525381 |
| | Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk | Q74784103 |
| | One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden | Q75344773 |
| | Frequency of germline and somatic BRCA1 mutations in ovarian cancer | Q77492989 |
| | BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study | Q81078213 |
| | Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report | Q81195452 |
| P433 | issue | 1 | |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 113-119 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Familial Cancer | Q15761917 |
| P1476 | title | Improved survival in BRCA2 carriers with ovarian cancer | |
| P478 | volume | 6 | |